Wall Street Analysts Think ImmunityBio (IBRX) Could Surge 184.43%: Read This Before Placing a Bet [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
While analysts' price targets can be misleading, a strong agreement among them about the company's earnings prospects and a recent increase in EPS estimates suggest a potential upside. Additionally, IBRX's Zacks Rank #2 (Buy) indicates a high likelihood of near-term price appreciation, making it a stock worth considering for investors. Shares of ImmunityBio (IBRX) have gained 41.1% over the past four weeks to close the last trading session at $5.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $14.25 indicates a potential upside of 184.4%. The average comprises three short-term price targets ranging from a low of $4.75 to a high of $30, with a standard deviation of $13.74. While the lowest estimate indicates a decline of 5.2% from the current price level, the most optimistic estimate points to a 498.8% upside. More than the range, one should note th
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio and nCartes partner to automate clinical trial data processes [Yahoo! Finance]Yahoo! Finance
- ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment [Yahoo! Finance]Yahoo! Finance
- ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentPR Newswire
- ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsPR Newswire
- ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months [Yahoo! Finance]Yahoo! Finance
IBRX
Earnings
- 11/12/24 - Beat
IBRX
Sec Filings
- 11/19/24 - Form 8-K
- 11/12/24 - Form 8-K
- 11/12/24 - Form 10-Q
- IBRX's page on the SEC website